SFRP2

Targeting the Untargetable: New Antibody Disrupts Key Protein in Aggressive Breast Cancer

Researchers at MUSC Hollings Cancer Center have developed an antibody targeting the SFRP2 protein, opening a new front in the battle against triple-negative breast cancer.

Read more

Breakthrough Antibody Targeting SFRP2 Protein Halts Aggressive Breast Cancer in Preclinical Models

Researchers at MUSC Hollings Cancer Center have developed a humanized antibody that neutralizes a key protein driving tumor growth and metastasis in triple-negative breast cancer.

Read more